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Excel). 
Three groups of patients (n=4 per group) were ana-
lyzed with non-mutated wild-type FLT3, FLT3-LM, and
FLT3-TKD (D835H, D835H, D835Y, del835). The in vitro
results from each group treated with SU5614 were com-
pared to those of the respective untreated control cells.
At the level of clonogenic progenitors (CFC) 2/4 patients
with wild-type FLT3, 3/3 with FLT3-LM (p<0.004) and
2/2 with FLT3-TKD responded to therapy with as much
as 100% reduction of the number of leukemic CFC as
compared to the untreated AML cells (Table 1). At the
level of HSC (LTC-IC), the compound achieved > 50%
cell killing in 3/4 (p<0.03) patients with  wild-type FLT3,
3/4 with FLT3-LM (p<0.04) and 2/4 with FLT3-TKD. The
response of both CFC as well as leukemic HSC to
SU5614 could not be predicted from the level of expres-
sion of FLT3 or the presence of activating mutations or
surface expression of c-KIT, a protein tyrosine kinase
also targeted by the SU5614 compound (data not shown).
As a control, CD34+ bone marrow stem cells from
healthy donors were analyzed in the same way. At the
level of CFC level SU5614 had considerable toxicity,
killing a mean (range) of 67.5 % (30-100) of the cells
(n=3). In addition, the compound eliminated normal HSC
(n=3) with a range between 78 – 100% after 24h incuba-
tion. These data demonstrate the efficacy of tyrosine
kinase inhibitors at eliminating leukemic stem cells in
AML patients with mutated as well as non-mutated
FLT3. However, the data also point to a considerable tox-
icity to normal HSC, which should be taken into account
in the management of patients with compromised nor-
mal hematopoiesis. 
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Malignant Lymphomas
Rituximab in patients with mucosal-associated
lymphoid tissue-type lymphoma of the ocular
adnexa 
Eight patients with ocular adnexal mucosal-asso-
ciated lymphpid tissue (MALT) lymphoma were
treated with rituximab, at diagnosis (n=5) or
relapse (n=3). All untreated patients achieved lym-
phoma regression, while relapsing patients had no
benefit. Four responding patients experienced early
relapse. The median time to progression was 5
months. The efficacy of rituximab in ocular adnex-
al lymphoma is lower than that reported for gastric
MALT lymphomas. haematologica 2005; 90:1578-1580
(http://www.haematologica.org/journal/2005/11/1578.html)
Any CD20-positive lymphoproliferative disorder is a
potentially suitable candidate for treatment with rituximab.
Significant rituximab activity has been reported in extran-
odal mucosal-associated lymphoid tissue (MALT) lym-
phomas.2 However, the clinical activity of this drug in
MALT lymphomas arising in different organs remains to be
defined.2 MALT-type ocular adnexal lymphoma is a very
indolent malignancy that would appear to be a suitable can-
didate for treatment with a drug that has an excellent safe-
ty profile, such as rituximab. However, the use of rituximab
in this setting has been only anecdotally investigated.1,3-5 
We report a series of eight patients with MALT-type ocu-
lar adnexal lymphoma treated with rituximab, at diagnosis
(patients #1 to 5) or relapse (patients #6 to 8) (Table 1).
Patients were treated with rituximab 375 mg/m2, weekly,
for four weeks, according to the conventional administra-
tion schedule which includes pre-medication. Patients did
not receive steroids or any other concomitant antineoplas-
tic therapy. CD20-positivity and MALT lymphoma histo-
type were confirmed both at diagnosis and relapse in all
cases. All patients had measurable disease in the ocular
adnexa, and two had concomitant systemic disease (Table
1). The study conformed to the tenets of the Declaration of
Helsinki. 
The tolerance to rituximab was excellent. All five
patients treated at diagnosis (patients #1 to 5) had an objec-
tive response, which was complete in three cases and par-
tial in two (Table 1); however, four of them experienced
local relapse and one of these four also had a systemic
relapse. Patients treated with rituximab for relapsed lym-
phoma (patients #6 to 8) did not achieve an objective
response. After a median follow-up from rituximab admin-
istration of 46 months, treatment had failed in all patients
but one (patient #4), with a median time to progression for
the entire series of 5 months. All patients are alive at a
median follow-up of 62 months.
This is the largest reported experience on patients with
MALT-type ocular adnexal lymphoma treated with ritux-
imab as a single agent. This drug has been associated with
modest activity in advanced MALT lymphomas,5 but with
a 73% response rate in a phase II trial on different extran-
odal MALT lymphomas.1 Consistently with our observa-
tions, reported response rates have been significantly high-
er among previously untreated patients than among relaps-
ing patients. The activity of rituximab has been reported to
be similar in gastric and non-gastric MALT lymphomas;1
however, an analysis according to extranodal site has not
been provided, and the median follow-up was 15 months,
thus preventing any conclusion being drawn about long-
term results. 
To date, only one paper focusing on the activity of ritux-
imab in ocular adnexal lymphoma is available.3 This study
included two patients with conjunctival MALT lymphoma
that had relapsed after radiotherapy in whom rituximab
then achieved durable remissions. The only patient in our
series who did not experience relapse after rituximab had a
conjunctival lymphoma. In another study,4 the role of ritux-
imab was investigated in eight patients with ocular adnex-
al lymphoma of different histotypes, including three
patients with MALT lymphoma. In that study,4 rituximab
was used in combination with chemotherapy and/or radio-
therapy, thus preventing any conclusion being drawn
about the real efficacy of the monoclonal antibody.
Consistently with our observations, however, two of the
three patients with MALT lymphoma experienced early
relapse after rituximab-containing therapy. Anecdotally, rit-
uximab activity has been reported in a few cases of ocular
adnexal lymphoma other than of MALT-type; stage, man-
agement and follow-up were variable.4,7,8
Our experience suggests a discrepancy between the
activity and efficacy of rituximab against MALT lym-
phomas arising in the ocular adnexa and those occurring in
the stomach. In fact, despite a high activity in both lym-
phomas, the efficacy of rituximab against ocular adnexal
lymphoma of MALT-type seems to be lower than that
reported for gastric MALT lymphoma.9 In a retrospective
series of 26 patients with gastric MALT lymphoma, 77% of
the patients responded to rituximab and only two patients
had relapses, after a median follow-up of 33 months.9
These results clearly contrast with the treatment failures
observed in seven of our eight patients and the median
time to progression of 5 months. These differences in the
efficacy of rituximab could be in part explained by the
known heterogeneity of extranodal MALT lymphomas,
which display a different natural behavior according to the
organ in which they arise.2
In conclusion, rituximab is highly active against newly
diagnosed ocular adnexal lymphoma, while it is inefficient
in relapsing patients. Its activity is similar to that observed
in other extranodal MALT lymphomas, but its long-term
efficacy is modest. The relapse rate in patients with ocular
adnexal MALT lymphoma is clearly higher than that
reported for gastric MALT lymphoma, suggesting that
MALT lymphomas arising in different organs could show
varied sensitivity to rituximab. Further investigations will
be needed to define the best role for rituximab in the man-
agement of extranodal MALT lymphomas. 
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Table 1. Stage, extent of disease, objective response, and duration
of response after rituximab. 
N. Sex/ Stage Orbital Systemic Therapy Objective TTP Site of
Age disease disease line# response* (mo.) relapse
1 F/56 IV lachrymal stomach, 1st CR 23 L
gland mediastinum &
axillary lymph n.
2 F/59 IV lachrymal - 1st CR 17 L
gland (bilateral)
3 F/74 I orbit - 1st PR 48 L + S§
4 F/38 I conjunctiva - 1st CR 37+
5 F/48 I conjunctiva - 1st PR 2 L
6 F/22 I orbit - 2nd PD 0 L
7 F/74 IV orbit bone marrow, 3rd PD 0 L
parotid gland &
cervical lymph n.
8 M/55 IV conjunctiva - 5th SD 5 L
(bilateral)
No patient had ECOG-PS >1, systemic symptoms or elevated levels of serum
lactate dehydrogenase . #Patient #6 had been previously treated with CEOP
chemotherapy, patient #7 with CEOP chemotherapy and orbital irradiation, and
patient #8 with orbital irradiation, CHOP chemotherapy, doxycycline, and
intralesional interferon. *Objective response was defined according to the WHO
criteria.6 CR: complete remission; PR: partial response, PD: progressive disease;
SD: stable disease; TTP: the time to progression was calculated from therapy
conclusion to the date of lymphoma progression or last date of follow-up;
“+” indicates the absence of lymphoma progression after therapy. L: local;
S: systemic. Preliminary data concerning patients #1 and 2 have been previously
reported.1 §Systemic relapse consisted of lymphomatous involvement of axillary
lymph nodes and subcutaneous nodules. 
